Document Detail


Thrombolysis with plasmin: implications for stroke treatment.
MedLine Citation:
PMID:  20876504     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plasmin is a direct-acting thrombolytic agent with a striking hemostatic safety advantage over plasminogen activators in animal models of thrombolysis and bleeding. In contradistinction to plasminogen activators, which risk bleeding at any effective thrombolytic dose, plasmin is tolerated without bleeding at several-fold higher amounts than those needed for thrombolysis. Plasmin has been safe in a current trial in patients with peripheral arterial or graft occlusion, and efforts are now directed toward therapy of stroke caused by cerebral artery occlusion. A rabbit (4 kg body weight) model of 2-hour, thrombin-induced middle cerebral artery occlusion using angiographic documentation of vascular patency and recanalization was used to perform a dose-ranging study of plasmin, delivered by catheter over a median duration of 10 minutes. Plasmin induced early recanalization in all animals (3 per group) within 10 minutes after discontinuation of 3, 2, or 1 mg of agent infusion. Control saline infusion failed to induce recanalization in 3 of 3 subjects. Plasmin rapidly induces middle cerebral artery recanalization, as determined in an angiogram-based animal model of arterial occlusion. Based on these data and other information, a phase I/IIa clinical trial of plasmin in human middle cerebral artery ischemic stroke has been initiated.
Authors:
Victor J Marder; Reza Jahan; Theresa Gruber; Abha Goyal; Vik Arora
Related Documents :
19409794 - Superficial temporal artery-middle cerebral artery bypass for ischemic atherosclerotic ...
10764264 - Prevention of complications resulting from endovascular carotid sacrifice: a retrospect...
9153124 - Transcranial doppler detected cerebral microembolism following carotid endarterectomy. ...
2183404 - Transcranial doppler ultrasound findings in middle cerebral artery occlusion.
11585794 - Notch signaling is required for arterial-venous differentiation during embryonic vascul...
1396924 - Convulsions, hemiparesis and central retinal artery occlusion due to left atrial myxoma...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  41     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-29     Completed Date:  2010-11-01     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S45-9     Citation Subset:  IM    
Affiliation:
Division of Hematology-Oncology, David Geffen School of Medicine at University of California Los Angeles, Room A3-29 Rehabilitation Building, 1000 Veteran Ave, Los Angeles, CA 90095, USA. vmarder@mednet.ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Disease Models, Animal
Fibrinolysin / therapeutic use*
Fibrinolytic Agents / therapeutic use
Infarction, Middle Cerebral Artery / drug therapy*
Rabbits
Stroke / drug therapy*
Thrombolytic Therapy / methods*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
P50 NS044378/NS/NINDS NIH HHS; P50 NS044378-08/NS/NINDS NIH HHS; R01 HL074051/HL/NHLBI NIH HHS; R01 HL074051-04/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.7/Fibrinolysin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What is the future of stroke prevention?: debate: polypill versus personalized risk factor modificat...
Next Document:  Ultrasound-assisted thrombolysis for stroke therapy: better thrombus break-up with bubbles.